Medical science has fundamentally reshaped the landscape of HIV, transforming it from a once-dire diagnosis into a manageable chronic condition. Modern antiretroviral (ARV) medications are now capable of suppressing the virus to levels where individuals living with HIV can lead long, healthy lives and, critically, prevent transmission to others. Furthermore, potent pharmaceutical interventions exist that can entirely block infection.
Despite these advancements, HIV remains a significant global health challenge. According to UNAIDS data, 1.3 million new infections occurred annually, and hundreds of thousands succumbed to AIDS-related illnesses. This disproportionately impacts developing regions, with sub-Saharan Africa bearing the heaviest burden. Even with remarkable progress, the world faces the risk of not achieving the United Nations’ ambitious goal of ending the global HIV epidemic by 2030.
This situation has sharpened the focus on the intricate interplay between cutting-edge medical science and the social hurdles that impede access to and adherence with life-saving treatments. To delve into these issues and address the critical question of what actions are necessary to conclude the HIV epidemic, New Scientist CoLab convened a roundtable discussion with leading HIV researchers. The event was organized and funded by ViiV Healthcare.
Confronting Transmission Dynamics
Kimberly Smith, Chief Scientific Officer and Head of Research and Development at ViiV Healthcare, posits that the challenge can be viewed through two distinct lenses. “One is the public health imperative: how do we reach a point where new HIV cases are eliminated?” she explained. “The other dimension involves exploring pathways to cure individuals living with HIV or to achieve long-term remission.”
Regarding the eradication of transmission, Smith articulated a straightforward strategy. It necessitates universal testing for all individuals at risk of HIV exposure to establish their status. Subsequently, all individuals diagnosed with HIV must commence state-of-the-art treatments capable of suppressing the virus. For those who test negative, access to pre-exposure prophylaxis (PrEP) is essential; this medication significantly diminishes the likelihood of contracting HIV.
This comprehensive approach is attainable today, owing to the dedicated work of researchers who developed effective treatments for people living with HIV. “The progress has been simply remarkable, a stark contrast to the situation 20 years ago,” commented Sally Hodder, Director of the Clinical and Translational Science Institute at West Virginia University. Joseph Eron, Professor of Medicine at the University of North Carolina, Chapel Hill, added, “As our therapies become more potent, we will gain additional opportunities to treat individuals in ways currently not possible. This will undoubtedly expand patient options.”
However, as Smith pointed out, while the plan is simple to articulate, its implementation is fraught with difficulty. Globally, out of the 40 million people currently living with HIV, approximately a quarter—9.3 million individuals—are not receiving essential treatment. Furthermore, new transmission rates are not declining sufficiently to meet the UN’s 2030 targets.
The Pervasive Impact of Stigma and Misinformation
The primary obstacle remains the persistent stigma surrounding HIV. Discrimination and the fear of social exclusion lead many to avoid testing or seeking treatment. “Forty years into this epidemic, HIV continues to be a profoundly stigmatized disease,” Smith observed.
Hodder highlighted that the enduring presence of misinformation has made dismantling this stigma exceptionally challenging. In sub-Saharan Africa, for instance, HIV is still widely, and incorrectly, believed to be transmissible through casual contact, fostering fear and social isolation. Many harbor the misconception that ARVs are toxic or lead to infertility. Critically, a large segment of the population remains unaware of the “U=U” principle—Undetectable = Untransmittable. This means that when HIV treatment successfully suppresses the virus to undetectable levels, it also renders the virus incapable of transmission.
Babafemi Taiwo, Vice President and Head of Early Development at ViiV Healthcare, emphasized the critical importance of combating misinformation. “We must disseminate accurate information and ensure it reaches everyone,” he stated. This necessitates enhanced training for healthcare providers. It also involves engaging trusted community leaders to counter false narratives, according to Hodder. Smith underscored the necessity of communicating the U=U message, noting, “If we can educate people on this, they will have no reason to fear individuals living with HIV.”
More information on U=U can be found at: viivhealthcare.com/u-equals-u/
Taiwo suggested that medical science advancements could contribute by reducing the frequency of ARV administration. “Extending treatment duration could potentially sever the link to the negative experiences associated with HIV,” he proposed. “However, medications alone will not resolve the issue. We must continue to address the social dimensions.”
Scientific Frontiers: Towards Remission
The second component of Smith’s two-pronged strategy to end the HIV epidemic presents its own set of substantial challenges, primarily of a scientific nature. The panel collectively considers a complete cure—the total eradication of the virus from the body—to be an unrealistic near-term prospect. Smith described HIV as a “cunning virus” that integrates its genetic material into long-lived cells, establishing latent ‘reservoirs’ that elude both pharmaceutical intervention and immune system detection. “We should transition from using the word ‘cure’ and instead focus on ‘remission’,” Hodder recommended.
Promising Avenues for Long-Term Control
Long-term remission refers to a state where the virus is controlled for extended periods, measured in months or years, without the need for continuous ARV therapy. Taiwo highlighted this as an area ripe for transformation through technological progress, referencing broadly neutralizing antibodies found in a small number of individuals years after infection that prevent HIV from infecting new cells. Developing similar agents in a laboratory setting could potentially delay viral rebound significantly.
Another promising strategy involves activating dormant HIV within cells and subsequently stimulating the immune system to eliminate the infected cells. “We are aware of individuals who live with HIV without therapy and have somehow managed to control their infection; we refer to them as ‘elite controllers’,” Eron stated. Taiwo expressed optimism about achieving greater understanding, suggesting that it brings us closer to keeping HIV at bay without the necessity of daily medication. The consensus, however, is that this remains an exceptionally difficult undertaking.
The Road Ahead: Optimism and Realism
Considering the prospects for achieving the UN’s goal of ending the HIV epidemic by 2030, or within the lifetimes of the experts present, a blend of optimism and realism emerged. “From a public health perspective, we possess all the necessary tools to halt transmission; we simply need to implement them with unwavering persistence,” asserted Smith. Regarding sustained remission, she acknowledged it as “a very significant challenge… but I remain optimistic that we will achieve it.”
Eron and Hodder expressed a more reserved outlook. “I wish the situation were different,” Eron admitted. Taiwo, however, offered a note of cautious optimism. “I will reframe your question: do I hope that HIV will be controlled within my lifetime? To that, I will say yes.”
An expert discussion is available to watch at: newscientist.com/viiv
For further information on ending HIV, visit ViiV Healthcare: viivhealthcare.com/ending-hiv/